MeiraGTx is a biotechnology company that focuses on developing gene therapies to treat inherited and acquired genetic disorders.
MeiraGTx has raised $125.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in July 2026.
MeiraGTx's investors include Sanofi, Perceptive Advisors, AlbionVC, ATW Partners, UCL Technology Fund.
MeiraGTx is headquartered in New York, United States.
MeiraGTx is a biotechnology company that focuses on developing gene therapies to treat inherited and acquired genetic disorders.
MeiraGTx is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MeiraGTx — Funding & Investors." VCBacked, July 7, 2026, https://www.vcbacked.co/company/meiragtx-new-york-2. Accessed August 22, 2026.
VCBacked. (2026). MeiraGTx — Funding & Investors. Retrieved August 22, 2026, from https://www.vcbacked.co/company/meiragtx-new-york-2
{{cite web |title=MeiraGTx — Funding & Investors |url=https://www.vcbacked.co/company/meiragtx-new-york-2 |website=VCBacked |access-date=August 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated